Medtronic’s decision to spin out its diabetes division into a separate entity marks a major shift — one that allows the medical device giant to shed a lower-margin, consumer-facing business, while ...

At the time of publication, Solara holds accreditation with the Better Business Bureau (BBB). The BBB currently gives the company a B grade. People on the BBB website give the company an average of ...

Deal Overview On May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business ...

Medtronic plc MDT recently launched an easy-to-use insulin infusion set, MiniMed Mio Advance, for the insulin-dependent diabetic patients in the United States. The launch expands Medtronic’s existing ...

Medtronic’s (NYSE: MDT) diabetes segment, which sells insulin pumps, continuous glucose monitoring (CGM) systems, and consumables has seen its revenue rise at a slower pace of 1.4% annually from $2.4 ...

Medtronic is the world’s largest pure-play medical device company. It is a dividend aristocrat, conservatively financed and well diversified. It seems like a great long-term investment. The company ...